On July 28, Centene rose over 6% in pre-market trading. On the news front, the company released its second-quarter earnings report. Management indicated during the earnings call that margins across all three major business lines are expected to improve next year, prompting a positive market response.

Notably, Centene had already delivered a strong Q2, reporting adjusted EPS of $3.37 versus the market consensus estimate of $2.13 — a beat of approximately 58% and a year-over-year increase of 16.21%. The company simultaneously raised its full-year guidance to above $3.40, well above the FactSet consensus estimate of $3.02. Multiple analysts subsequently raised their price targets, with Truist setting a $71 target with a Buy rating and JPMorgan adjusting to $60 while maintaining Neutral.

Centene is a leading multinational healthcare enterprise focused on providing integrated, cost-effective services for government-sponsored and commercial healthcare programs, with emphasis on under-insured and uninsured populations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)